Becton, Dickinson and Company (NYSE:BDX) Receives $280.00 Consensus Price Target from Brokerages

Shares of Becton, Dickinson and Company (NYSE:BDX) have earned an average rating of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $280.00.

Separately, Barclays raised their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, February 5th.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BDX. Commonwealth Equity Services LLC lifted its holdings in shares of Becton, Dickinson and Company by 0.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 84,714 shares of the medical instruments supplier’s stock valued at $21,901,000 after buying an additional 648 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its holdings in Becton, Dickinson and Company by 3.4% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 25,820 shares of the medical instruments supplier’s stock worth $6,675,000 after purchasing an additional 859 shares in the last quarter. FinTrust Capital Advisors LLC increased its position in Becton, Dickinson and Company by 39.1% during the third quarter. FinTrust Capital Advisors LLC now owns 544 shares of the medical instruments supplier’s stock worth $141,000 after buying an additional 153 shares during the last quarter. Stratos Wealth Partners LTD. raised its holdings in Becton, Dickinson and Company by 13.2% during the third quarter. Stratos Wealth Partners LTD. now owns 13,627 shares of the medical instruments supplier’s stock valued at $3,523,000 after buying an additional 1,591 shares in the last quarter. Finally, Stratos Wealth Advisors LLC raised its holdings in Becton, Dickinson and Company by 1.3% during the third quarter. Stratos Wealth Advisors LLC now owns 4,099 shares of the medical instruments supplier’s stock valued at $1,060,000 after buying an additional 51 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $234.68 on Friday. Becton, Dickinson and Company has a 1-year low of $229.40 and a 1-year high of $287.32. The stock has a 50-day moving average of $238.45 and a two-hundred day moving average of $240.27. The company has a market cap of $67.80 billion, a P/E ratio of 51.69, a P/E/G ratio of 1.93 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.86 earnings per share. As a group, analysts anticipate that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.62%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.